ShockWave Medical stock (US8130281086): trading steady ahead of pending Boston Scientific takeover

ShockWave Medical shares traded in a narrow range on Nasdaq in recent sessions as market participants continued to focus on the pending takeover by Boston Scientific at USD 335 per share in cash, a transaction that values the California-based cardiovascular device group at roughly USD 13 billion, according to a definitive agreement announced on 03/04/2024 and detailed in company and SEC filings.

The United States remains the home base for ShockWave Medical, with the stock listed on Nasdaq under the ticker SWAV and reporting in USD, and the proposed acquisition by Massachusetts-based Boston Scientific has become the central driver of trading sentiment while closing conditions and regulatory approvals are finalized.

The stock most recently traded modestly below the USD 335 offer price, reflecting a typical merger-arbitrage discount that incorporates remaining deal risks and the expected timing of completion, with volumes lighter than during the initial announcement phase, based on recent Nasdaq trading data as of late May 2026.

The company’s investor communications emphasize that, under the terms of the definitive agreement, Boston Scientific will acquire all outstanding ShockWave Medical shares for USD 335 in cash, subject to customary closing conditions including regulatory clearances and shareholder approvals, and that the parties initially guided to a closing in late 2024, according to the joint press release and subsequent SEC disclosures.

In Germany, ShockWave Medical is also available to retail investors via off-exchange platforms such as Tradegate under the SWAV ticker, trading in euros and providing an additional access point for investors who prefer local settlement and EUR quotations, according to German trading venue data as of 05/31/2026.

The deal spotlight comes on top of ShockWave Medical’s most recent quarterly earnings release, in which the company reported strong growth in revenue from its intravascular lithotripsy systems for coronary and peripheral artery disease, reinforcing the strategic rationale that Boston Scientific cited when agreeing to pay a substantial premium over ShockWave Medical’s pre-announcement share price.

The company’s latest 10-Q filing with the U.S. Securities and Exchange Commission underlines that ShockWave Medical continues to operate independently until the transaction closes, while acknowledging that the pending merger has introduced certain constraints and incremental costs tied to integration planning and regulatory review processes.

As of: 02/06/2026

By the editorial team - specialized in equity coverage.

ShockWave Medical: core business model

ShockWave Medical focuses on catheter-based intravascular lithotripsy platforms that help treat calcified arterial lesions, with revenue primarily generated from disposable IVL catheters and related capital equipment used in coronary and peripheral vascular procedures worldwide.

Latest quarterly results for ShockWave Medical at a glance

In its most recent reported quarter, ShockWave Medical announced double-digit year-on-year revenue growth driven by broader adoption of its intravascular lithotripsy technology in both coronary and peripheral indications, according to the company’s quarterly earnings release dated 05/06/2024.

The 05/06/2024 report highlighted that U.S. hospitals remained the largest revenue contributor, while international markets, particularly in Europe, also expanded as reimbursement frameworks and clinical guidelines increasingly recognized IVL as a treatment option, and management pointed to continued gross margin strength supporting ongoing investment in product development and clinical evidence generation.

Conclusion

For now, trading in ShockWave Medical centers on the pending USD 335-per-share cash acquisition by Boston Scientific, with the share price hovering near but below the agreed offer level. The latest quarterly results, showing continued uptake of intravascular lithotripsy systems, provide fundamental support for the deal rationale even as investors watch for final regulatory and closing milestones.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.